Concepts (218)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Heart Transplantation | 19 | 2020 | 328 | 2.240 |
Why?
|
| Tissue and Organ Procurement | 5 | 2022 | 164 | 1.200 |
Why?
|
| Heart Failure | 14 | 2019 | 1180 | 1.060 |
Why?
|
| Thyroxine | 1 | 2022 | 62 | 0.810 |
Why?
|
| Hemodynamics | 9 | 2022 | 705 | 0.720 |
Why?
|
| Tissue Donors | 5 | 2022 | 195 | 0.700 |
Why?
|
| Graft Rejection | 8 | 2020 | 458 | 0.570 |
Why?
|
| Heart-Assist Devices | 4 | 2019 | 221 | 0.510 |
Why?
|
| Medical Staff, Hospital | 1 | 2013 | 44 | 0.460 |
Why?
|
| Models, Statistical | 2 | 2013 | 448 | 0.440 |
Why?
|
| Practice Patterns, Physicians' | 2 | 2016 | 504 | 0.430 |
Why?
|
| Furosemide | 2 | 2010 | 45 | 0.430 |
Why?
|
| Biostatistics | 1 | 2012 | 43 | 0.420 |
Why?
|
| Brain Death | 3 | 2022 | 34 | 0.380 |
Why?
|
| Bayes Theorem | 1 | 2012 | 307 | 0.370 |
Why?
|
| Diuretics | 2 | 2008 | 97 | 0.360 |
Why?
|
| Sodium Potassium Chloride Symporter Inhibitors | 1 | 2010 | 11 | 0.350 |
Why?
|
| Algorithms | 2 | 2014 | 1196 | 0.320 |
Why?
|
| Mesalamine | 1 | 2008 | 6 | 0.310 |
Why?
|
| Ventricular Function, Right | 2 | 2019 | 103 | 0.310 |
Why?
|
| Myocarditis | 1 | 2008 | 49 | 0.300 |
Why?
|
| Anti-Inflammatory Agents, Non-Steroidal | 2 | 2013 | 240 | 0.290 |
Why?
|
| Influenza Vaccines | 1 | 2006 | 56 | 0.250 |
Why?
|
| Humans | 34 | 2022 | 68618 | 0.240 |
Why?
|
| Tissue and Organ Harvesting | 1 | 2004 | 49 | 0.240 |
Why?
|
| Acute Disease | 5 | 2019 | 658 | 0.220 |
Why?
|
| Adult | 14 | 2022 | 21403 | 0.210 |
Why?
|
| Biopsy | 5 | 2013 | 540 | 0.210 |
Why?
|
| Isolated Noncompaction of the Ventricular Myocardium | 1 | 2022 | 5 | 0.210 |
Why?
|
| Heart | 2 | 2006 | 850 | 0.210 |
Why?
|
| Pulmonary Artery | 2 | 2019 | 323 | 0.200 |
Why?
|
| Methylprednisolone | 1 | 2022 | 99 | 0.200 |
Why?
|
| Vasoconstrictor Agents | 1 | 2022 | 107 | 0.200 |
Why?
|
| Cardiomyopathy, Dilated | 1 | 2022 | 106 | 0.200 |
Why?
|
| Middle Aged | 18 | 2019 | 21147 | 0.190 |
Why?
|
| Female | 21 | 2019 | 38074 | 0.180 |
Why?
|
| Ventricular Function, Left | 2 | 2018 | 481 | 0.180 |
Why?
|
| Male | 21 | 2019 | 37321 | 0.180 |
Why?
|
| Vascular Resistance | 2 | 2019 | 179 | 0.180 |
Why?
|
| Mycophenolic Acid | 2 | 2013 | 62 | 0.170 |
Why?
|
| Treatment Outcome | 9 | 2018 | 7029 | 0.170 |
Why?
|
| Survival Rate | 5 | 2019 | 1056 | 0.160 |
Why?
|
| Probability | 2 | 2010 | 245 | 0.160 |
Why?
|
| Shock, Cardiogenic | 1 | 2018 | 23 | 0.160 |
Why?
|
| Stroke Volume | 2 | 2019 | 586 | 0.160 |
Why?
|
| Retrospective Studies | 8 | 2019 | 7277 | 0.150 |
Why?
|
| Risk Factors | 6 | 2017 | 5731 | 0.150 |
Why?
|
| Thrombosis | 1 | 2019 | 218 | 0.150 |
Why?
|
| Prosthesis Implantation | 1 | 2018 | 83 | 0.150 |
Why?
|
| Heart Ventricles | 2 | 2019 | 738 | 0.140 |
Why?
|
| Hemorrhage | 1 | 2019 | 328 | 0.140 |
Why?
|
| Natriuretic Agents | 2 | 2008 | 9 | 0.140 |
Why?
|
| Aged | 12 | 2019 | 14862 | 0.140 |
Why?
|
| Thyroid Hormones | 1 | 2016 | 31 | 0.140 |
Why?
|
| Cardiovascular Agents | 1 | 2017 | 82 | 0.140 |
Why?
|
| Hypothyroidism | 1 | 2016 | 24 | 0.140 |
Why?
|
| Anticoagulants | 1 | 2019 | 356 | 0.140 |
Why?
|
| Natriuretic Peptide, Brain | 2 | 2008 | 101 | 0.130 |
Why?
|
| Registries | 1 | 2019 | 733 | 0.130 |
Why?
|
| Suicide | 1 | 2017 | 116 | 0.130 |
Why?
|
| Infusions, Intravenous | 2 | 2010 | 334 | 0.130 |
Why?
|
| Drug Therapy, Combination | 3 | 2008 | 649 | 0.130 |
Why?
|
| Societies, Medical | 1 | 2017 | 403 | 0.120 |
Why?
|
| Tricuspid Valve Insufficiency | 1 | 1994 | 25 | 0.120 |
Why?
|
| Cardiography, Impedance | 1 | 2014 | 14 | 0.120 |
Why?
|
| Pulmonary Edema | 1 | 2014 | 37 | 0.120 |
Why?
|
| Brain | 2 | 2022 | 2176 | 0.120 |
Why?
|
| Dose-Response Relationship, Drug | 3 | 2017 | 1745 | 0.110 |
Why?
|
| Hospitals, University | 2 | 2011 | 169 | 0.110 |
Why?
|
| Heart Block | 1 | 1993 | 49 | 0.110 |
Why?
|
| Stochastic Processes | 1 | 2012 | 27 | 0.110 |
Why?
|
| Depressive Disorder | 1 | 2017 | 621 | 0.110 |
Why?
|
| Follow-Up Studies | 4 | 2014 | 3259 | 0.110 |
Why?
|
| Cardiac Catheterization | 3 | 2019 | 419 | 0.100 |
Why?
|
| Adenosine | 1 | 1993 | 165 | 0.100 |
Why?
|
| Kaplan-Meier Estimate | 1 | 2013 | 536 | 0.100 |
Why?
|
| Sirolimus | 1 | 2013 | 118 | 0.100 |
Why?
|
| Heart Arrest | 1 | 1993 | 113 | 0.100 |
Why?
|
| Echocardiography | 3 | 2019 | 515 | 0.100 |
Why?
|
| United States | 7 | 2019 | 7367 | 0.100 |
Why?
|
| Regression Analysis | 1 | 2013 | 737 | 0.100 |
Why?
|
| Mediastinal Diseases | 1 | 2010 | 15 | 0.090 |
Why?
|
| Lymphatic Diseases | 1 | 2010 | 27 | 0.090 |
Why?
|
| Injections, Intravenous | 1 | 2010 | 215 | 0.080 |
Why?
|
| Waiting Lists | 2 | 2002 | 104 | 0.080 |
Why?
|
| Prospective Studies | 3 | 2014 | 3705 | 0.080 |
Why?
|
| Heart Diseases | 1 | 2011 | 276 | 0.080 |
Why?
|
| Natriuresis | 1 | 2008 | 13 | 0.080 |
Why?
|
| Antidiuretic Hormone Receptor Antagonists | 1 | 2008 | 6 | 0.080 |
Why?
|
| Purinergic P1 Receptor Antagonists | 1 | 2008 | 10 | 0.080 |
Why?
|
| Sodium Chloride Symporter Inhibitors | 1 | 2008 | 8 | 0.080 |
Why?
|
| Ultrafiltration | 1 | 2008 | 35 | 0.080 |
Why?
|
| Mineralocorticoid Receptor Antagonists | 1 | 2008 | 25 | 0.080 |
Why?
|
| Nitrates | 1 | 2008 | 61 | 0.080 |
Why?
|
| Drug Administration Schedule | 1 | 2010 | 567 | 0.080 |
Why?
|
| Chi-Square Distribution | 1 | 2010 | 546 | 0.080 |
Why?
|
| Postoperative Complications | 4 | 2019 | 1615 | 0.080 |
Why?
|
| Vasoconstriction | 1 | 2008 | 81 | 0.080 |
Why?
|
| Myocardium | 4 | 2022 | 1204 | 0.080 |
Why?
|
| Syndrome | 1 | 2008 | 255 | 0.080 |
Why?
|
| Drug Hypersensitivity | 1 | 2008 | 35 | 0.080 |
Why?
|
| Colitis, Ulcerative | 1 | 2008 | 53 | 0.080 |
Why?
|
| Drug Resistance | 1 | 2008 | 223 | 0.070 |
Why?
|
| HLA-A Antigens | 1 | 2007 | 8 | 0.070 |
Why?
|
| Cohort Studies | 1 | 2013 | 2358 | 0.070 |
Why?
|
| Antibodies, Anti-Idiotypic | 1 | 2007 | 43 | 0.070 |
Why?
|
| Practice Guidelines as Topic | 2 | 2016 | 772 | 0.070 |
Why?
|
| Immunosuppressive Agents | 2 | 2013 | 514 | 0.070 |
Why?
|
| Antigen-Antibody Complex | 1 | 2007 | 175 | 0.070 |
Why?
|
| Immunoglobulin G | 2 | 2007 | 481 | 0.070 |
Why?
|
| Transplantation | 1 | 2006 | 23 | 0.070 |
Why?
|
| Virus Diseases | 1 | 2006 | 31 | 0.070 |
Why?
|
| Antibodies | 2 | 2020 | 241 | 0.060 |
Why?
|
| Blood Flow Velocity | 1 | 2005 | 172 | 0.060 |
Why?
|
| Adolescent | 5 | 2011 | 8912 | 0.060 |
Why?
|
| Hormones | 1 | 2004 | 42 | 0.060 |
Why?
|
| Diagnosis, Differential | 1 | 2008 | 1140 | 0.060 |
Why?
|
| Heart Rate | 1 | 2006 | 568 | 0.060 |
Why?
|
| Severity of Illness Index | 1 | 2010 | 1851 | 0.060 |
Why?
|
| Aorta | 1 | 2005 | 316 | 0.060 |
Why?
|
| Muscle, Smooth, Vascular | 1 | 2005 | 317 | 0.060 |
Why?
|
| Incidence | 3 | 2014 | 1603 | 0.060 |
Why?
|
| Risk Assessment | 1 | 2010 | 2007 | 0.060 |
Why?
|
| Antibodies, Monoclonal | 1 | 2005 | 511 | 0.050 |
Why?
|
| Hemofiltration | 1 | 2002 | 7 | 0.050 |
Why?
|
| Cadaver | 1 | 2002 | 136 | 0.050 |
Why?
|
| Young Adult | 2 | 2011 | 5717 | 0.050 |
Why?
|
| Digoxin | 1 | 2002 | 24 | 0.050 |
Why?
|
| Cardiotonic Agents | 1 | 2002 | 71 | 0.050 |
Why?
|
| Hypolipidemic Agents | 1 | 2002 | 82 | 0.050 |
Why?
|
| Anti-Arrhythmia Agents | 1 | 2002 | 98 | 0.050 |
Why?
|
| Angiotensin Receptor Antagonists | 1 | 2002 | 155 | 0.050 |
Why?
|
| Adrenergic beta-Antagonists | 1 | 2002 | 189 | 0.050 |
Why?
|
| Angiotensin-Converting Enzyme Inhibitors | 1 | 2002 | 202 | 0.050 |
Why?
|
| Monitoring, Physiologic | 1 | 2002 | 219 | 0.050 |
Why?
|
| Blood Pressure | 1 | 2006 | 1451 | 0.050 |
Why?
|
| Aged, 80 and over | 1 | 2010 | 4848 | 0.050 |
Why?
|
| Allografts | 1 | 2020 | 63 | 0.040 |
Why?
|
| HLA Antigens | 1 | 2020 | 82 | 0.040 |
Why?
|
| Time Factors | 3 | 2018 | 4655 | 0.040 |
Why?
|
| Kidney | 1 | 2004 | 945 | 0.040 |
Why?
|
| Elasticity | 1 | 2019 | 103 | 0.040 |
Why?
|
| Referral and Consultation | 1 | 2002 | 383 | 0.040 |
Why?
|
| Self Care | 1 | 2002 | 253 | 0.040 |
Why?
|
| Intracranial Hemorrhages | 1 | 2019 | 80 | 0.040 |
Why?
|
| Blood Coagulation | 1 | 2019 | 123 | 0.040 |
Why?
|
| Double-Blind Method | 2 | 2017 | 1738 | 0.040 |
Why?
|
| Endocardium | 2 | 1997 | 101 | 0.040 |
Why?
|
| Diabetes Insipidus | 1 | 1997 | 5 | 0.040 |
Why?
|
| Postmortem Changes | 1 | 1997 | 15 | 0.040 |
Why?
|
| Heart Function Tests | 1 | 1997 | 33 | 0.040 |
Why?
|
| Endomyocardial Fibrosis | 1 | 1997 | 5 | 0.040 |
Why?
|
| Blood Coagulation Disorders | 1 | 1997 | 45 | 0.040 |
Why?
|
| Water-Electrolyte Balance | 1 | 1997 | 43 | 0.040 |
Why?
|
| Hypothermia | 1 | 1997 | 37 | 0.040 |
Why?
|
| Nitric Oxide Donors | 1 | 2017 | 54 | 0.040 |
Why?
|
| Education | 1 | 1997 | 83 | 0.040 |
Why?
|
| Respiration | 1 | 1997 | 91 | 0.040 |
Why?
|
| Adaptation, Physiological | 1 | 2018 | 189 | 0.040 |
Why?
|
| Ethics, Medical | 1 | 1997 | 86 | 0.040 |
Why?
|
| Prosthesis Design | 1 | 2018 | 301 | 0.040 |
Why?
|
| Clinical Protocols | 1 | 2016 | 172 | 0.030 |
Why?
|
| Health Care Surveys | 1 | 2016 | 239 | 0.030 |
Why?
|
| South Carolina | 3 | 2011 | 2752 | 0.030 |
Why?
|
| Puerperal Disorders | 1 | 1994 | 20 | 0.030 |
Why?
|
| Recovery of Function | 1 | 2018 | 506 | 0.030 |
Why?
|
| Echocardiography, Doppler | 1 | 1994 | 87 | 0.030 |
Why?
|
| Suture Techniques | 1 | 1994 | 75 | 0.030 |
Why?
|
| Survival Analysis | 2 | 2006 | 714 | 0.030 |
Why?
|
| Electric Impedance | 1 | 2014 | 131 | 0.030 |
Why?
|
| South America | 1 | 2013 | 8 | 0.030 |
Why?
|
| Everolimus | 1 | 2013 | 26 | 0.030 |
Why?
|
| Asia | 1 | 2013 | 59 | 0.030 |
Why?
|
| North America | 1 | 2013 | 112 | 0.030 |
Why?
|
| Equipment Design | 1 | 2014 | 500 | 0.030 |
Why?
|
| Cardiomyopathies | 1 | 1994 | 167 | 0.030 |
Why?
|
| Europe | 1 | 2013 | 196 | 0.030 |
Why?
|
| Cardiac Resynchronization Therapy | 1 | 2014 | 119 | 0.030 |
Why?
|
| Feasibility Studies | 1 | 2014 | 652 | 0.030 |
Why?
|
| Ultrasonography, Interventional | 1 | 2013 | 119 | 0.030 |
Why?
|
| Australia | 1 | 2013 | 235 | 0.030 |
Why?
|
| Hospitalization | 1 | 2017 | 978 | 0.020 |
Why?
|
| Child | 3 | 2011 | 6405 | 0.020 |
Why?
|
| Sentinel Lymph Node Biopsy | 1 | 2010 | 53 | 0.020 |
Why?
|
| Hospital Mortality | 1 | 2011 | 384 | 0.020 |
Why?
|
| Reproducibility of Results | 1 | 2014 | 2077 | 0.020 |
Why?
|
| Patient Selection | 2 | 2006 | 592 | 0.020 |
Why?
|
| Immunoglobulin M | 1 | 2007 | 172 | 0.020 |
Why?
|
| Flow Cytometry | 1 | 2007 | 489 | 0.020 |
Why?
|
| Comprehensive Health Care | 1 | 2006 | 26 | 0.020 |
Why?
|
| Kidney Function Tests | 1 | 2005 | 114 | 0.020 |
Why?
|
| Infant, Newborn | 1 | 2011 | 2455 | 0.020 |
Why?
|
| Opportunistic Infections | 1 | 2005 | 33 | 0.020 |
Why?
|
| Antineoplastic Agents | 1 | 2013 | 1070 | 0.020 |
Why?
|
| Infant | 1 | 2011 | 2891 | 0.020 |
Why?
|
| Cyclosporine | 1 | 2005 | 121 | 0.020 |
Why?
|
| Diuresis | 1 | 2004 | 20 | 0.020 |
Why?
|
| Immunohistochemistry | 1 | 2007 | 1174 | 0.020 |
Why?
|
| Program Development | 1 | 2006 | 240 | 0.020 |
Why?
|
| Child, Preschool | 1 | 2011 | 3187 | 0.010 |
Why?
|
| Antibodies, Monoclonal, Humanized | 1 | 2005 | 151 | 0.010 |
Why?
|
| Cardiac Output | 1 | 2004 | 133 | 0.010 |
Why?
|
| Disease Management | 1 | 2006 | 248 | 0.010 |
Why?
|
| Inpatients | 1 | 2005 | 208 | 0.010 |
Why?
|
| Adrenal Cortex Hormones | 1 | 2005 | 186 | 0.010 |
Why?
|
| Pulmonary Wedge Pressure | 1 | 2004 | 102 | 0.010 |
Why?
|
| Combined Modality Therapy | 1 | 2004 | 951 | 0.010 |
Why?
|
| Acute Kidney Injury | 1 | 2004 | 232 | 0.010 |
Why?
|
| Pilot Projects | 1 | 2005 | 1342 | 0.010 |
Why?
|
| Logistic Models | 1 | 2005 | 1420 | 0.010 |
Why?
|
| Coronary Artery Disease | 1 | 2007 | 696 | 0.010 |
Why?
|
| Prevalence | 1 | 2005 | 1619 | 0.010 |
Why?
|
| Tomography, X-Ray Computed | 1 | 2010 | 2324 | 0.010 |
Why?
|
| Coronary Angiography | 1 | 2005 | 866 | 0.010 |
Why?
|
| Communication | 1 | 2002 | 329 | 0.010 |
Why?
|
| Biomarkers | 1 | 2004 | 1593 | 0.010 |
Why?
|
| Actuarial Analysis | 1 | 1997 | 23 | 0.010 |
Why?
|
| Cause of Death | 1 | 1997 | 241 | 0.010 |
Why?
|